Treatment with SCS is still common among patients with CRSwNP with or without comorbid asthma, despite the availability of ...
Tezepelumab is associated with beneficial changes in nasal polyp gene expression in patients with chronic rhinosinusitis with ...
The FDA has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis.
My sinuses have been bunged up for years. I'm constantly blowing my nose. I use nasal decongestants but those don't seem to ...
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients ...
People with allergic fungal rhinosinusitis taking Dupixent (dupilumab) saw significant improvement in congestion and sinus ...
The FDA has approved dupilumab (Dupixent) for the treatment of allergic fungal rhinosinusitis (AFRS), marking the first approved therapy for this condition. The approval applies to adults ...
Women using estrogen-containing contraceptives vs. not using any systemic hormonal contraceptives had reduced odds for ...
New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster ...
The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.
FDA approves Regeneron and Sanofi's Dupixent for allergic fungal sinusitis in patients 6 years and older with prior surgery ...
LIBERTY-AFRS-AIMS met its primary endpoint with a 50% reduction in CT sinus opacification at week 52 versus 10% with placebo (P<.0001).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results